Hyperfine (HYPR) Debt Ratio (2020 - 2026)

Hyperfine (HYPR) posted Debt Ratio of 0.22 for Q1 2026, up 41393.29% on a QoQ basis from 0.0 in Q1 2023.

Hyperfine (HYPR) Debt Ratio (2020 - 2026) Analysis & Trends

Hyperfine's Debt Ratio history runs 5 years deep, the most recent figure standing at 0.22 for Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.22 (changed N/A YoY) and the FY2021 annual result came in at 0.01, up 122.87% from the prior year.
Debt Ratio was 0.22 for Q1 2026 at Hyperfine, up from 0.0 in the prior quarter.
Across five years, Debt Ratio topped out at 0.22 in Q1 2026 and bottomed at 0.0 in Q3 2022.
A 3-year average of 0.04 and a median of 0.0 in 2023 frame the typical range for Debt Ratio.
Peak annual rise in Debt Ratio reached 3.37% in 2023, while the deepest fall reached 3.37% in 2023.
Hyperfine's Debt Ratio stood at 0.0 in 2022, then grew by 27.46% to 0.0 in 2023, then jumped by 41393.29% to 0.22 in 2026.
Business Quant data shows HYPR's Debt Ratio at 0.22 in Q1 2026, 0.0 in Q1 2023, and 0.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	0.31
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	0.32
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	0.30
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	0.04
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	0.30
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	0.27
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	0.30
10	Hyperfine	92.81 Mn	51.53 Mn	1.98 Mn	0.22

Download Data